Illustration of amyloid plaques (orange) among brain cells
Science Photo Library/Alamy
In early July, the US Food and Drug Administration (FDA) approved a treatment called donanemab for people with early-stage Alzheimer’s disease. It is the second drug shown to slow the condition’s progression, and the third FDA-authorised medication that clears the amyloid proteins that accumulate in the brains of people with Alzheimer’s.
The FDA’s approval of three new drugs – donanemab, lecanemab and aducanumab – in just over three years has led some to declare a leap forward in Alzheimer’s disease treatment. Japan, South Korea, China,…
By Jan Cohen-Cruz. In this episode, personal relationships between Finn and Jan and Alex and…
The Rangers and Leafs are battling it to see who can be the worse team…
US regulators have clarified that tokenized securities will receive the same capital treatment as their…
According to biographer Marc Eliot, in To The Limit: The Untold Story of the Eagles,…
Here is a link. The post Democracy continues appeared first on Marginal REVOLUTION. Source link
Some students walk into class ready to talk. Others enter quietly, holding their backpack close,…